E Engelsman
Impact in
- Cancer Research top 5%
- Breast Cancer Treatment Studies
- Oncology top 5%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
Papers in
- Co-authors
- Willem Boogerd (1 shared paper)J.-P. Persijn (5 shared papers)Augustinus A. M. Hart (1 shared paper)F. J. Cleton (4 shared papers)Richard Sylvester (5 shared papers)Nicole Rotmensz (3 shared papers)J. Wildiers (3 shared papers)R.D. Rubens (3 shared papers)
- Journals
- The Lancet (2 papers)British Journal of Cancer (2 papers)Thrombosis and Haemostasis (1 paper)Breast Cancer Research and Treatment (1 paper)Clinical Biochemistry (1 paper)
- Partner nations
- NetherlandsBelgiumUnited Kingdom
In The Last Decade
E Engelsman
36 papers receiving 910 citations
Peers
Comparison fields: 5 of 69
- Cancer Research 346
- Oncology 460
- Genetics 260
- Genetics 92
- Pulmonary and Respiratory Medicine 240
Countries citing papers authored by E Engelsman
This map shows the geographic impact of E Engelsman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Engelsman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Engelsman more than expected).
Fields of papers citing papers by E Engelsman
This network shows the impact of papers produced by E Engelsman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Engelsman. The network helps show where E Engelsman may publish in the future.
Co-authors
The 25 scholars most cited alongside E Engelsman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1991 | 173 | |
| 2 | 1991 | 129 | |
| 3 | 1974 | 80 | |
| 4 | 1989 | 79 | |
| 5 | 1985 | 77 | |
| 6 | 1973 | 72 | |
| 7 | 1987 | 58 | |
| 8 | 1975 | 49 | |
| 9 | 1975 | 49 | |
| 10 | 2003 | 38 | |
| 11 | 1985 | 31 | |
| 12 | CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. | 1980 | 27 |
| 13 | 1975 | 26 | |
| 14 | 1988 | 17 | |
| 15 | 1984 | 17 | |
| 16 | 1974 | 16 | |
| 17 | 1970 | 16 | |
| 18 | 1985 | 14 | |
| 19 | 1994 | 9 | |
| 20 | Life with cytostatic drugs. | 1980 | 9 |
About E Engelsman
E Engelsman is a scholar working on Genetics, Oncology, Cancer Research, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 37 papers that have together received 1.0k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (13 papers), Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (7 papers), Lymphoma Diagnosis and Treatment (4 papers), Advanced Breast Cancer Therapies (2 papers), Thyroid Disorders and Treatments (2 papers), Cancer Risks and Factors (2 papers) and Meningioma and schwannoma management (2 papers). The work is most often cited by research in Cancer Research (346 citations), Oncology (460 citations), Genetics (260 citations), Genetics (92 citations) and Pulmonary and Respiratory Medicine (240 citations). E Engelsman has collaborated with scholars based in Netherlands, Belgium and United Kingdom. Frequent co-authors include Willem Boogerd, J.-P. Persijn, Augustinus A. M. Hart, F. J. Cleton, Richard Sylvester, Nicole Rotmensz, J. Wildiers, R.D. Rubens, M. De Jong‐Bakker and H. G. Kwa. Their work appears in journals such as The Lancet, British Journal of Cancer, Thrombosis and Haemostasis, Breast Cancer Research and Treatment and Clinical Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.